The cephalosporin compounds in severe neonatal infection.
The new cephalosporin compounds have increased in vitro activity against gram-negative enteric bacilli and penetrate well into cerebrospinal fluid. Moreover, their pharmacokinetic properties are favorable and their safety seems adequate, although insufficiently evaluated to date. Interest has been focused on them as therapeutic agents for neonatal sepsis and meningitis caused by Enterobacteriaceae. In this review the third generation cephalosporins are evaluated for their possible use in the neonates; opinions are based on currently available data. It is concluded that moxalactam and cefotaxime and probably also ceftriaxone and ceftazidime represent valuable alternatives to aminoglycosides for therapy of severe neonatal infection.
D002439:Cefotaxime / Q000031:analogs & derivatives / Q000627:therapeutic use; D002442:Ceftazidime; D002443:Ceftriaxone; D002511:Cephalosporins / Q000627:therapeutic use*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D008581:Meningitis / Q000188:drug therapy; D009070:Moxalactam / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy
D002511:Cephalosporins; D002443:Ceftriaxone; D002442:Ceftazidime; D002439:Cefotaxime; D009070:Moxalactam